

**JAK2 Antibody (Center) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP14491c****Specification**

---

**JAK2 Antibody (Center) Blocking Peptide - Product Information**Primary Accession [O60674](#)**JAK2 Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 3717**Other Names**

Tyrosine-protein kinase JAK2, Janus kinase 2, JAK-2, JAK2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**JAK2 Antibody (Center) Blocking Peptide - Protein Information****Name** JAK2 ([HGNC:6192](#))**Function**

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN- beta, IFN-gamma and multiple interleukins (PubMed:<a href="http://www.uniprot.org/citations/7615558" target="\_blank">7615558</a>). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:<a href="http://www.uniprot.org/citations/9618263" target="\_blank">9618263</a>). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that

leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:<a href="http://www.uniprot.org/citations/21368206" target="\_blank">21368206</a>). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:<a href="http://www.uniprot.org/citations/20098430" target="\_blank">20098430</a>). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:<a href="http://www.uniprot.org/citations/21423214" target="\_blank">21423214</a>). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:<a href="http://www.uniprot.org/citations/19783980" target="\_blank">19783980</a>).

#### **Cellular Location**

Endomembrane system; Peripheral membrane protein. Cytoplasm. Nucleus

#### **Tissue Location**

Ubiquitously expressed throughout most tissues.

### **JAK2 Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **JAK2 Antibody (Center) Blocking Peptide - Images**

### **JAK2 Antibody (Center) Blocking Peptide - Background**

This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis.

### **JAK2 Antibody (Center) Blocking Peptide - References**

Qian, J., et al. Clin. Chim. Acta 411 (23-24), 2097-2100 (2010) ; Andrikovics, H., et al. Leukemia 24(10):1809-1813(2010) Beer, P.A., et al. Blood 116(6):1013-1014(2010) Weston, H., et al. Intern Med J (2010) In press ; Ma, W., et al. PLoS ONE 5 (8), E12165 (2010) :